The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation
The acquisition of ADL BioPharma now makes WACKER owner of the entire plant, with total fermentation capacities of just under 3,000 cubic meters
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
The company will submit its comprehensive response on these observations to the US FDA within the stipulated time
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
A special technique of jet injection is used to make vaccination almost painless and totally needleless.
Subscribe To Our Newsletter & Stay Updated
